Method for producing radionuclides of high purity and high specific activity
Patent Information
- Application Number
- JP2023558941
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-15
- Filing Date
- 2021-12-09
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2041-12-09
AI Technical Summary
Current methods for producing radionuclides face limitations in achieving high purity, specific activity, and yield, particularly for medical applications, which restrict their availability and industrial use, especially in nuclear medicine and radiotherapy.
A method combining target irradiation with a particle beam, followed by chemical extraction and mass separation, to produce radionuclides with high specific radioactivity, using commercial accelerators and reactors, and employing techniques like chromatography and mass separation to enhance purity and yield.
Enables the production of radionuclides with high purity and specific activity, facilitating their use in medical applications such as theranostic treatments and imaging, and addressing the limitations of existing production methods.
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of production of radionuclides of high purity and high specific activity, for example for medical use on an industrial scale. [Background technology]
[0002] Radioactive isotopes, or radionuclides, are widely used in the life sciences, research, and medicine fields, for example in nuclear medicine.
[0003] In nuclear medicine, they are used in diagnostic imaging and radiotherapy, especially for cancer diseases. To reach the target, radioisotopes can be attached to molecules / vehicles and injected in solution (e.g. citrate) or independently (Zimmermann, Nuclear Medicine: Radioactivity for Diagnosis and Therapy - 2017 - EDP Science Edition). Radionuclides can be attached to the vehicle using chelators and linkers. Chelators are substances capable of forming several bonds to a single atom or ion, also defined as polydentate ligands. When using vehicles, it is necessary to find suitable biological targets that will attach to tumor cells without harming normal cells. This is possible by using peptides or antibodies that are preferentially taken up by specific receptors, selecting those target receptors that are more frequently present on tumor cells than on normal cells. Radioisotopes labeled to the same vehicle, preferably peptides or antibodies, that guarantee imaging and therapy are defined as theranostic (or theragnostic) radioisotopes (Langbein et al: J Nucl Med. 2019 Sep;60(Suppl 2):13S-19S).
[0004] One such important application of radioisotopes is in the diagnosis and treatment of diseases, e.g., cancer. For example, there has been considerable progress in the last two decades in the use of radiolabeled tumor-selective peptides and monoclonal antibodies in the diagnosis and treatment of several types of cancer. The concept of localizing cytotoxic radionuclides to cancer cells is an important complement to traditional forms of radiotherapy. In theory, the interaction of the radiopharmaceutical with the target cells can focus the absorbed radiation dose at the cancer cell site, minimizing damage to normal surrounding cells and tissues (Zhejiang et al. Univ Sci B. 2014 Oct; 15(10): 845-863; Zukotynski et al. Biomark Cancer. 2016; 8(Suppl 2): 35-38). The choice of radioisotope is based on the nature of the radiation emitted, its physical properties (e.g., energy, half-life, and decay series), and its chemical properties. Based on the radiation emitted, radioisotopes can be further divided into gamma (γ) ray emitters, beta (positron β+ or electron β-) particle emitters, and alpha (α) particle emitters, Auger emitters, or combinations thereof. Further advances in the field of nuclear medicine will require the investigation of the use of new isotopes, new sources, and methods of isotope production.
[0005] Three main direct or indirect nuclear processes leading to the production of the intended radioisotope can be defined and identified as radionuclide production methods: nuclear reactions carried out by using particle accelerators, e.g. cyclotrons, linear accelerators and electron accelerators, nuclear reactions carried out in nuclear reactors, and the production of optimal radioisotopes obtained by the so-called chemical dissolution process inside the generator. Furthermore, the above production methods can be combined with other techniques to improve the quality of the product. Radioisotopes can be produced by the transmutation of nuclei by bombarding target nuclei with charged particles (mainly protons, deuterons, or alpha particles). These charged particles need to be accelerated to energies of at least a few MeV to overcome the Coulomb barrier of the target nuclei to enable nuclear reactions. As a result, particle accelerators are required. Due to their practical properties and high current capabilities for the entire energy range of interest (10-100 MeV), cyclotrons have been almost exclusively chosen since the 1950s as the most convenient choice for radioisotope production, except for a few therapeutic radionuclides that are more conveniently produced in nuclear reactors. However, only a few radioisotopes can be produced in cyclotrons with high radionuclide purity and high production yields. To improve the availability of some other nuclides, for example, US Patent Publication No. 20170169908 shows the use of a 70 MeV cyclotron with an online mass separation system, which means the simultaneous or pseudo-simultaneous irradiation of a target by the cyclotron and its separation by online mass separation for the production of radionuclides. However, these methods imply the constraint of the target to be irradiated, which must have determined properties, which may potentially reduce the overall yield (e.g. porosity, evaporation temperature, etc.) and limit the radioisotopes that can be produced with high efficiency. Another example is US Patent No. 9202600 (US9202600B2) (Canadian Patent No. 2594829 (CA2594829C) and British Patent No. 2436508 (GB2436508B)), which shows the production of radionuclides by high energy accelerators and mass separation. The main problem is again the availability of high yields of produced radionuclides, which allows their industrial application. Summary of the Invention
[0006] However, currently used methods for the production of radioisotopes have reached their limits and there is a strong need for new and improved methods to increase the availability of new and currently used isotopes, particularly in terms of isotopic purity, yield, specific activity, and range of available radionuclides.
[0007] The growing proliferation of positron emission tomography (PET) / single photon emission computed tomography (SPECT) imaging, and the development of whole-body radionuclide therapy, have created an increasing demand to prepare radioisotopes with higher radiochemical and radionuclide purity than previously achieved, and to ensure adequate production yields for industrial commercialization.
[0008] Furthermore, the realization of breakthroughs in the development of targeted drug delivery systems for new methods of cancer therapy is limited due to the lack of availability of existing radionuclides with optimal decay properties for such applications.For radioligand therapy (RLT), it is essential that the radionuclide purity is high enough to guarantee patient safety and minimize the risks associated with potential hazardous contaminants, both from a toxicity standpoint and from a radioactive waste standpoint.
[0009] Furthermore, sometimes radionuclides can only be produced in research facilities, and the production of radionuclides, especially for medical applications, corresponds to a small portion of the available time. Thus, these radionuclides are not routinely available for distribution and use, understating their potential use, for example, for nuclear medicine applications and research. With regard to the increasing demand for certain radionuclides, and the difficulties faced in providing them by commercial accelerators, it is important to provide methods that allow the optimization of the use of the commercial accelerators, especially during times dedicated to medical applications.
[0010] This can be achieved by using commercial accelerators and / or nuclear reactors for the production of the desired radionuclides. However, sometimes the purity and specific activity of the produced batches of radionuclides are not high enough for receptor-targeted applications. Thus, the produced batches require further processing to meet their requirements; for example, chemical separation can increase batch purity and mass separation can increase radionuclide purity.
[0011] Valuably, the inventors have found that a combined radionuclide production process, chemical extraction, and mass separation provides cost-effective, flexible, and efficient production of a wide variety of radionuclides on a large scale with high radionuclide purity and specific activity that enables their use for receptor-targeted applications.
[0012] It is therefore an object of the present invention to provide a method for producing radionuclides of high purity and high specific activity, the specific activity being understood as the ratio of the activity of the produced radionuclide to the total mass of all nuclides belonging to the same element as the produced radionuclide. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] In that respect, a) irradiating a target of interest with a particle beam to obtain an irradiated target containing a radionuclide of interest; b) chemically extracting the desired radionuclide from the irradiation target and increasing its chemical purity; c) providing a method for producing a radionuclide of high specific activity, the method comprising the step of mass separating the target radionuclide to obtain a radionuclide of high specific activity. The particles of the beam can be protons, neutrons, photons, deuterons or alpha particles. For accelerator-based production, proton beams are preferred, and for reactor-based production, neutron beams are preferred. The particles of the beam can cause nuclear reactions to result in an irradiated target containing the desired radionuclide. The main purpose of step b) is to remove a large proportion of the major impurities, thereby increasing the batch purity and thus the efficiency of step c).
[0014] Another object of the invention resides in the high specific activity of the radionuclides obtained by the process of the invention. Yet another object of the invention is the medical use of the radionuclides of high specific activity according to the invention.The invention relates to radionuclides of high specific activity according to the invention for use in a method of therapeutic treatment of the human or animal body or in a diagnostic method carried out on the human or animal body.
[0015] Radionuclides of interest are defined as known radionuclides, preferably said known radionuclides are alpha emitters, beta (-) emitters, beta (+) emitters, gamma emitters, Auger emitters. Preferably, said known radionuclides are those of the following list of radionuclides herein: F-18, Sc-43, Sc-44, Sc-47, Cr-51, Mn-52m, Fe-52, Co-55, Cu-61, Cu-62, Cu-64, Ga-66, Cu-67, Ga-67, Ga-68, As-72, As-76, Rb-82, Y-86, Zr-89, Y-90, Ru-97, Tc-99m, Rh-105, In-111, Ag111, Sn-117m, Sn-121, I-123, I-124, I-131, Pr-142, Pr-143, Tb-149, Pm-149, Pm-151, Tb-152, Sm -153, Tb-155, Gd-157, Gd-159, Tb-161, Er-165, Dy-166, Ho-166, Tm-167, Er-169, Yb-169, Tm,-172, Yb-175, Lu-177, Re-186, Re-188, Au-198, Au-199, Pb-203, At-211, Pb-212, Bi-212, Bi-213, Ac-225, Ac-227, and Th-229, and preferably selected from Sc-43, Sc-44, Sc-47, Tb-149, Tb-152, Tb-155, Tb-161, Lu-177, other lanthanides, and Ac-225.
[0016] The present invention makes it possible to produce batches of radionuclides that are difficult or impossible to produce with sufficient radionuclide purity by other means. These radionuclides are produced with high purity and high specific activity, allowing a wide variety of applications, for example both imaging and therapeutic protocols in the medical field. The radionuclides are available, for example, to hospitals and research centers for in-vivo and in-vitro studies. Preferably, the radionuclides of interest are selected from those that allow theranostic therapy. Theranostic approaches in nuclear medicine combine imaging and therapy using the same or at least very similar molecules that are differently radiolabeled or given in different doses. For example, copper-67, iodine-131, and lutetium-177 are gamma and beta emitters, and therefore these substances can be used for both imaging and therapy. Furthermore, different isotopes of the same element can also be used for theranostic purposes, such as iodine-123 (gamma emitter) and iodine-131 (gamma and beta emitter). More recent examples are yttrium-86 / yttrium-90, or terbium isotopes (Tb): Tb-152 (beta+ emitter), Tb-155 (gamma emitter), Tb-149 (alpha emitter), and Tb-161 (beta-emitter) [Table 1]. Furthermore, different isotopes of different chemical elements, such as radioactive lanthanides, e.g. Lu-177 (therapeutic gamma and beta emitters), and radionuclides of similar chemical properties, e.g. Ga-68 (beta+ emitter), can also be used for theranostic purposes.
[0017] [Table 1]
[0018] Preferably, said high specific activity radionuclide is selected from isotopes of terbium, in which case said target of interest preferably comprises natural or enriched gadolinium, preferably metal, oxide or chloride, and is preferably irradiated with an accelerator proton beam.
[0019] In fact, there is a potential growing demand in the medical industry for terbium isotopes that is difficult to meet with current production means. For example, natural gadolinium, either metallic or oxide, can be a good compromise between the availability of raw materials and the production yield of terbium radionuclides. The chemical separation will mainly involve the elements terbium and gadolinium, and the mass separation will mainly involve the terbium nuclide.
[0020] Preferably, the therapeutic radionuclide of high specific activity selected is erbium Er-169. The target for said purpose then preferably comprises natural or (in Er-168) enriched erbium, preferably metal, oxide, nitrate or chloride, and is irradiated with neutrons, preferably in a nuclear reactor.
[0021] In fact, there is a potential demand for high specific activity erbium in the medical industry that cannot be achieved by current production methods. For example, highly enriched Er-168 in nitrate and oxide is a good target material that would achieve high production yields. The chemical separation would mainly involve the elements ytterbium and erbium, and the mass separation would mainly involve the erbium nuclide.
[0022] Other preferred high specific activity radionuclides may be selected from isotopes of scandium, in which case the target for said purpose preferably comprises titanium metal, more preferably natural titanium metal which is widely available and allows high scandium radionuclide production yields.
[0023] In fact, there is an increasing demand in the medical industry for scandium isotopes that is difficult to meet with current production methods. Titanium metal is a good compromise between raw material availability and scandium radionuclide production yield. The chemical separation will mainly involve the elements scandium and titanium, while the mass separation will mainly involve the scandium nuclides.
[0024] The high specific activity radionuclide may also be selected from isotopes of actinium, and the intended target preferably comprises natural thorium.
[0025] In fact, there is an increasing demand in the medical industry for actinium isotopes that is difficult to meet with current production means. Natural thorium is a good compromise between raw material availability and actinium radionuclide production yield. The chemical separation will mainly involve the elements thorium and actinium, while the mass separation will mainly involve the actinium nuclides.
[0026] The high specific activity radionuclide may also be selected from isotopes of lutetium, and the target of interest preferably comprises metallic ytterbium.
[0027] In fact, there is an increasing demand in the medical industry for isotopes of lutetium that is difficult to meet with current production methods. Metallic ytterbium is a good compromise between the availability of raw materials and the radionuclide production yield of lutetium. The chemical separation will mainly involve the elements lutetium and ytterbium, while the mass separation will mainly involve the lutetium nuclide.
[0028] The main steps of the present invention are described below. The above steps can also be carried out in different orders or repeated several times to ensure the production of high quality products.
[0029] Step a): Target irradiation The method for producing said high specific activity radionuclides comprises step a) of irradiating a target of interest with a particle beam, preferably a proton beam, to obtain an irradiated target containing the radionuclide of interest. Said proton beam of step a) may exhibit an energy comprised between 18 and 200 MeV, preferably between 30 and 70 MeV. Such an energy offers an interesting compromise between the difficulty of generating such a beam and the radionuclide production yield. This proton beam may be provided by a commercial cyclotron, for example the Arronax IBA C70 cyclotron located in Nantes, France.
[0030] Step b): Chemical extraction The method for producing said high specific activity radionuclides comprises a step b) of chemically extracting a batch of the desired radionuclide from said irradiation target.
[0031] The target of interest in step b may be dissolved in an acid solution.
[0032] This dissolution results in a solution of the target material and the radionuclide, which is the input to a chemical separation process for the production of a particular radionuclide. Preferably, the chemical separation process is chromatography.
[0033] Step b) may for example comprise dissolving the target of interest in an acid solution, for example containing nitric acid (HNO3), the solution thus obtained may then be passed through a resin.
[0034] Step b) above may comprise a liquid-liquid extraction.
[0035] Liquid-liquid extraction allows a good compromise between the cost of materials required for chemical separation and the volume of the experimental setup for advanced target mass separations.
[0036] The above step b) may also comprise a liquid-solid extraction.
[0037] Liquid-solid extraction can be a good compromise between the cost of materials required for chemical separation and the volume of the experimental setup for highly targeted mass separations.
[0038] This chemical separation step provides an improvement in radiochemical purity, thus removing the target material relative to the desired radionuclide, thereby increasing the efficiency of the mass separation in step c) above and increasing the yield obtained from the present invention.
[0039] A method for producing a high specific activity radionuclide according to any embodiment includes the steps of: pouring the liquid solution obtained in step b) onto a support, preferably a metal support; heating said liquid solution on said support to concentrate said radionuclides on said support; Inserting said support containing said radionuclide of interest into a mass separation system. The method may further comprise a target coupling step b2) comprising:
[0040] If gadolinium is the desired target, step b) may comprise dissolving metallic gadolinium in an acid solution, preferably containing nitric acid. The resulting solution may then be passed through a resin. This step is described in more detail in Example 2.
[0041] This process reduces the gadolinium content, which can translate into improved efficiency of the subsequent mass separation.
[0042] If the radionuclide of high specific activity is selected from the isotopes of scandium, step b) may comprise dissolving metallic titanium in an acid solution, preferably a hydrobromic acid (HBr) solution. This process may require a difference in potential to be applied to the metal to favor dissolution. The resulting solution is then dissolved in acid and passed through a resin.
[0043] This process reduces the titanium content, which can translate into improved efficiency of the subsequent mass separation.
[0044] Step c): Mass separation Contaminants belonging to the same element cannot be separated by chemical separation. Therefore, a physical separation process, preferably mass separation, is considered. The mass separation process can achieve higher specific activity and higher radionuclide purity.
[0045] The method for producing said high specific activity radionuclides comprises step c) of mass separating a batch of the desired radionuclides to obtain radionuclides of high specific activity, said mass separation using conventionally used target ovens for evaporating the atoms, ionizers for ionizing said atoms, extraction electrodes for post-accelerating said ions, magnets enabling said mass separation, and collection supports.
[0046] Ionization of the atoms in the mass separation process can be achieved by conventional ion sources. Finally, laser ionization can be considered to improve ionization efficiency.
[0047] Step d): Second chemical separation (optional) The method for producing radionuclides of high specific activity can further comprise a step d) consisting of a second chemical separation purification carried out after the mass separation step.
[0048] This is an optional step, unlikely to be performed due to the very pure product extracted after mass separation. However, it is of interest whenever there is an interest in defining a compromise between the time required for a very good first chemical separation before mass separation and the final product. In those cases, the chemical separation can be divided into two steps: a first chemical separation before mass separation and a second chemical separation after mass separation. Furthermore, this second purification may be required depending on how the radionuclides are recovered after mass separation. In fact, different methods can be used to recover the radionuclides. For example, if the radionuclides are deposited on a metal plate, this second chemical separation step is required to recover the radionuclides produced.
[0049] Other features, details, and advantages are set forth in the following detailed description and drawings. [Brief description of the drawings]
[0050] [Figure 1] 1 shows a flow chart illustrating the radionuclides predicted to be produced upon irradiation of a natural titanium target depending on the energy of the irradiation beam. [Diagram 2] 1 shows a flow chart of theoretical scandium yields obtained starting from various targets. EXAMPLES
[0051] [Example 1] Production of Scandium-47 preface Determining the best starting material is very important.
[0052] In the case of the production of scandium-47, natural titanium has been found to be a good compromise between availability, cost, and physical properties; alternatively, enriched titanium or calcium may also be used. As shown in FIG. 1, the production of Sc-47 from natural titanium is possible with proton beam energies below 70 MeV. However, other contaminants are also produced, the most important being Sc-46, which has a rather long life span, which is undesirable when considering Sc-47 for medical applications. This is why appropriate purification and mass separation steps, as described in the present invention, are essential to obtain products that can be used for medical applications, such as radionuclides with high production yields, high purity, and high specific activity.
[0053] The production yields evaluated and shown in FIG. 2 should be determined. Table 2 below lists theoretical calculations of potential contaminants produced by irradiation of a natural titanium target. The calculations were performed with the software MCNPx. Most of the listed contaminants can be removed by chemical separation. The main concern is Sc-46, which requires additional separation, e.g. mass separation. The ratio of the yield of Sc-46 compared to Sc-47 is almost 10% at end of bombardment (EOB), which is too high for medical applications, especially RTL applications.
[0054] [Table 2]
[0055] A theoretical approximation can be made by considering a metallic titanium disk with a thickness of 4 mm and a diameter of 26 mm. The metallic disk is subjected to a 70 MeV, 25 μA proton beam for three days (three days corresponds to the half-life of Sc-47).
[0056] After irradiation, the batch of radionuclides of interest is chemically separated and purified from the irradiated target. A potential difference is applied to the irradiated target to favor its dissolution in dilute HBr. The acid solution is then modified with dilute HNO3 to meet the conditions for placing in the resin. After washing with a suitable medium, Sc is eluted from the resin. The eluted solution has a very reduced titanium content compared to the initial solution. This greatly reduces the Ti-47 that cannot be separated during the mass separation step. This drawback can be overcome using laser ionization.
[0057] The specific activity per unit target mass is 65.8 MBq / mg at this point in the process.
[0058] The batch of radionuclides is then separated according to a mass separation process, in which atoms and thus molecules with mass 47 can be selectively extracted and collected on dedicated foils, for example gold supports coated with Zn, which undergo chemical processes to recover Sc-47 from the foil material.
[0059] The specific activity per unit target mass is 3.08x10 of the maximum theoretical specific activity at the end of the process according to the present invention. 4 Approximately 2.8x10 GBq / mg 3 It is in GBq / mg.
[0060] To further increase the radiochemical purity, after mass separation, a further chemical separation can be foreseen to remove residual titanium content from the produced batch of radionuclides.
[0061] [Example 2] For the production of Tb-155 (this also applies to two other Tb radionuclides, e.g. Tb-149 and Tb-152), three metallic gadolinium foils (25 μm thick) purchased from Goodfellow were used as targets. They were irradiated with 55 MeV protons at 30 μA for 12 hours in an Arronax cyclotron. This energy is chosen to obtain 33 MeV on the target based on our target design. The Tb-155 / Gd ratio at EBO was 1:2.7E6. The main radioactive contaminants are listed in the table below.
[0062] [Table 3] After irradiation, the three targets are removed from the target holder.
[0063] The chemical process consists of two chromatographic columns packed with Ln resin: column 1 (500 mm, V = 36.9 mL) and column 2 (250 mm, V = 8.6 mL). All elutions are performed at 1 mL / mn using a high-pressure pump. The Gd foil was dissolved in concentrated nitric acid (2M) and then evaporated to dryness. The dry residue was taken up in 3 mL of dilute nitric acid (0.75M) and loaded onto column 1, which had been previously washed to remove impurities and prepared with 0.75M HNO3. Under these conditions, gadolinium is less retained by the column than Tb, and most of it can be removed by washing the column with 40 mL of 0.75M HNO3 followed by 80 mL of 1.M HNO3. The terbium element is then eluted using 45 mL of 1 M HNO3 followed by 40 mL of 2 M HNO3. 85 mL are then evaporated to dryness and collected in 3 mL of 0.75 M HNO3 for the second purification step using column 2. The solution is poured into column 2 and traces of Gd are eluted using 12 mL of 0.75 M HNO3 followed by 15 mL of 1 M HNO3. Tb is then collected using 10 mL of 1 M HNO3 followed by 15 mL of 2 M HNO3. These 25 mL are then evaporated to dryness.
[0064] After cooling, the residue is recovered in 3 mL of 0.01 M HNO3. The resulting terbium solution is then poured into a tantalum boat covered with rhenium, which is suitable for a mass separation target system, particularly the CERN-MEDICIS target system since that was the one studied in this example. The sample is then heated to evaporate the acid, resulting in a terbium residue deposited on the rhenium support. The tantalum boat is then loaded to CERN and inserted into the CERN-MEDICIS target for mass separation. At the end of these chemical steps, the Tb155:Gd is less than 1:20, a very large improvement from the EOB ratio.
[0065] The target system was installed at CERN MEDICIS and a mass separator was placed for the extraction of terbium. The target was heated to 600A and the laser optimized for mass 159. A laser on / off ratio of 620 / 110pA was measured. The target was heated to 700A and optimized at 22.3kV. A primary current of (FC70)726nA was measured. The separation current was 241pA with the laser on and 245pA with the laser off. 194pA was measured at the sample and 5.8pA at the collimator. The target was heated to 750A and the current at the sample was 600pA (3.8pA at the collimator). The maximum current measured at the sample was 900pA (3pA at the collimator). The recovery time was 22 hours.
[0066] The target loaded onto the separator had an activity of 230 MBq and the recovered Tb-155 was 2.9 MBq, corresponding to an overall efficiency of 1.3% and a radionuclide purity greater than 99.9%.
[0067] Further chemical purification is required to extract the Tb-155 atoms from the embedded zinc-coated gold foil.
[0068] [Example 3] A natural Er-2O3 target was irradiated with a 72 MeV proton beam to produce Tm-165, 167 and 168 radionuclides. The target with a total activity of 150 MBq was transferred to the target ion source unit and connected to the MEDICIS target station; isotope mass separation was performed at mass 167 over 4 days, with ion source temperatures between 2100 and 2190 °C, beam energy of 60 kV, and target steadily increased over 4 days from 1760 °C to 2300 °C. Total ion beam currents were included between 14 nA and 8 uA. Measured beam intensities during collection at A=167 varied between 53 pA and 118 nA, with a Gaussian beam profile of σH1.0 mm x V0.74 mm. The separated radioactivity was collected over three metal foils and partially distributed to the chamber. The initial Tm-167 activity in the target before separation was 77 MBq and the recorded separated activity was 42 MBq at the end of recovery; this provides a separation efficiency of 54%. Radionuclide purity was assessed by a high-purity germanium detector and found to be better than 99.99%, with Tm-165 and Tm-168 contaminant activities below the detection threshold.
[0069] conclusion In these examples, it has been shown that the method of the present invention can provide a desired radionuclide with high specific activity, high purity, and potentially high yield. The examples also show how chemical separation prior to mass separation improves its efficiency, and how important the mass separation step is to enhance radionuclide purity.
Claims
1. a) irradiating a target of interest with a particle beam to obtain an irradiated target containing a radionuclide of interest; b) chemically extracting the radionuclide of interest from the irradiation target; c) A method for producing high specific activity radionuclides, comprising the step of mass separating a batch of the desired radionuclides to obtain high specific activity radionuclides.
2. 2. The method for producing radionuclides of high specific activity according to claim 1, wherein the particle beam of step a) is a proton beam exhibiting an energy comprised between 18 and 200 MeV.
3. 2. The method of producing high specific activity radionuclides as set forth in claim 1, wherein step b) comprises dissolving the target of interest in an acid solution.
4. 2. The method of producing high specific activity radionuclides as set forth in claim 1, wherein said high specific activity radionuclides are selected from isotopes of terbium and said intended target comprises metallic gadolinium.
5. 5. The method for producing high specific activity radionuclides according to claim 4, wherein step b) comprises dissolving metallic gadolinium in a nitric acid solution and passing the resulting solution through the resin.
6. 2. The method of producing high specific activity radionuclides as set forth in claim 1, wherein said high specific activity radionuclides are selected from isotopes of scandium and said intended target comprises metallic titanium.
7. 7. The method for producing high specific activity radionuclides according to claim 6, wherein step b) comprises exposing metallic titanium to a HBr solution while applying a voltage, dissolving the solution in an acid, and passing the resulting solution through a resin.
8. 2. The method for producing high specific activity radionuclides according to claim 1, wherein step b) comprises liquid-liquid extraction.
9. 2. The method for producing high specific activity radionuclides according to claim 1, wherein step b) comprises liquid-solid extraction.
10. 2. The method of producing high specific activity radionuclides as set forth in claim 1, wherein said high specific activity radionuclides are selected from isotopes of actinium and said intended target comprises natural thorium.
11. 2. The method of producing high specific activity radionuclides as set forth in claim 1, wherein said high specific activity radionuclides are selected from isotopes of erbium and said intended target comprises natural erbium.
12. 2. The method of producing high specific activity radionuclides as set forth in claim 1, wherein said high specific activity radionuclides are selected from isotopes of lutetium and said intended target comprises metallic ytterbium.
13. pouring the liquid solution obtained in step b) onto a support; heating said liquid solution on said support to concentrate said radionuclide on said support; inserting said support containing said radionuclide of interest into a mass separator.
2. The method for producing a radionuclide of high specific activity according to claim 1, further comprising a target coupling step b2) comprising:
14. A method for producing a radionuclide of high specific activity as described in claim 13, wherein the support in step b2) is a metal support.
15. 2. The method for producing a radionuclide of high specific activity according to claim 1, further comprising a second chemical separation and purification step d2) after the mass separation step.
16. A radionuclide of high specific activity obtained by the method of claim 1.
17. 17. A radionuclide of high specific activity according to claim 16 for use in a method of therapeutic treatment of the human or animal body or in a diagnostic method performed on the human or animal body.
